Vasomune Therapeutics
Business Services · Canada · 11-50 Employees
View Company Info for Free
Overview
Headquarters
180 John St Ste 305, Toronto, Ontario, M...Phone Number
(647) 475-5660Website
www.vasomune.comRevenue
$5.2 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
2
1
1
1
About Vasomune Therapeutics
Vasomune Therapeutics is a private biotechnology company focused on developing innovative therapies to enhance the body's defense against diseases by targeting vascular dysfunction and leak. Their lead drug candidate, Pegevongitide (AV-001), aims to activate the Tie2 receptor to improve vascular stability and counteract inflammation, particularly in conditions like pneumonia and Acute Respiratory Distress Syndrome (ARDS). The company is addressing a critical need in the medical field, as there are currently no effective treatments for vascular leak. Vasomune's approach represents a novel multifactorial strategy that contrasts with traditional therapies aimed at specific pathogens.Explore more
Vasomune Therapeutics Org Chart
GH
Vice President, Finance
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Vasomune Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Vasomune Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Vasomune Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Vasomune Therapeutics
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Vasomune Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Vasomune Therapeutics had a recent Job posting/layoffs
Check out if Vasomune Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once Vasomune Therapeutics has new funding data
Earning: See what the market has to say on Vasomune Therapeutics recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Vasomune Therapeutics as Masked Content
Find 3 more new buyers
Compare Similar Companies to Vasomune Therapeutics
Compare insights from companies similar to Vasomune Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Vasomune Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Vasomune Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Vasomune Therapeutics.
Vasomune Therapeutics Tech Stack
A closer look at the technologies used by Vasomune Therapeutics
Vasomune Therapeutics News & Media
Vasomune and AnGes Announce Drug Candidate AV-001 Receives Positive IDSMB Recommendation to move to the High-Dose Cohort for AV001-004 Phase 2a Study
TORONTO--(BUSINESS WIRE)-- #ARDS--Vasomune Therapeutics Inc., a clinical-stage biopharmaceutical company focused on the development of AV-001 for the treatment of diseases associated with vascular dysfunction, announced today that their lead drug candidate AV-001 has received a positive recommendation from the Independent Data and Safety Monitoring Board (IDSMB) to escalate to the high-dose cohort in their AV001-004 Phase 2a Study, NCT05123755. “We are pleased to announce that the IDSMB recommenVasomune Therapeutics Receives US FDA Fast Track Designation for Novel Investigational Medicine AV-001
TORONTO--(BUSINESS WIRE)-- #ARDS--Vasomune Therapeutics, Inc., has announced today that the US Food and Drug Administration (FDA) granted Fast Track designation for AV-001 for the prevention or treatment of moderate-to-severe ARDS in patients hospitalized with viral and/or bacterial respiratory infections. AV-001 is a first-in-class fully synthetic PEGylated peptide targeting the Tie2 receptor which plays a critical role in vascular stability, barrier integrity and endothelial quiescence, particVasomune Therapeutics Announces Poster Presentation at the American Thoracic Society International Conference
TORONTO--(BUSINESS WIRE)-- #ARDS--Vasomune selected to present peer-reviewed Phase 1 development data as a Late-Breaking scientific poster at the 2024 ATS conference.American Thoracic Society Selects Vasomune Therapeutics, Inc., to Present the AV-001 Development Update at the 2024 Respiratory Innovation Summit
TORONTO--(BUSINESS WIRE)-- #ARDS--Vasomune Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of diseases associated with vascular dysfunction, has been selected by the American Thoracic Society to showcase its lead drug candidate AV-001 at the 2024 Respiratory Innovation Summit (RIS). Vasomune’s lead drug candidate AV-001 is a first-in-class fully synthetic PEGylated peptide targeting the Tie2 receptor. Activation of
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Vasomune Therapeutics
Sign Up For FreeTo access detailed company insights
Vasomune Therapeutics is a private biotechnology company focused on developing innovative therapies to enhance the body's defense against diseases by targeting vascular dysfunction and leak. Their lead drug candidate, Pegevongitide (AV-001), aims to activate the Tie2 receptor to improve vascular stability and counteract inflammation, particularly i... Read More
